Phase IIb Protocol 011: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction in Treatment-Naive Patients Demonstrates Very Low HIV-1 RNA Levels in Patients With Wk 48 Protocol-Defined Virologic Failure

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

Don Smith, MD Released: April 20, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

CCO commentary by Daniel R. Kuritzkes, MD, on emerging HIV treatment option data presented at CROI 2021

Daniel R. Kuritzkes, MD Released: April 6, 2021